SCHEMBL2017261

SCHEMBL2017261

CC(C)(C)OC(=O)N1CCN(c2cccc(-c3ccc4c(c3)C(C)(C)CCC4(C)C)c2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 4/20 0.49
PDK2 Q15119 1/20 0.49
USP30 Q70CQ3 1/20 0.48
HSD17B10 Q99714 4/20 0.47
USP2 O75604 3/20 0.47
CYP3A4 P08684 2/20 0.47
ALDH1A1 P00352 3/20 0.47
MAPT P10636 2/20 0.47
LMNA P02545 1/20 0.47
RARA P10276 1/20 0.47
RARB P10826 1/20 0.47
RARG P13631 1/20 0.47
ADORA2A P29274 1/20 0.47
CRBN Q96SW2 1/20 0.45
CTSS P25774 1/20 0.45
CTSK P43235 1/20 0.45
MAPK1 P28482 2/20 0.44
CYP1A2 P05177 2/20 0.44
PIK3CA P42336 1/20 0.44
HPGD P15428 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8515292 0.88 MAPT (0.46) GPR119PDK2ALDH1A1MAPTLMNA
SCHEMBL2014735 0.85 WNT3A (0.46) GPR119PDK2ALDH1A1MAPTLMNA
SCHEMBL8514584 0.84 RARB (0.56) HSD17B10USP2CYP3A4ALDH1A1RARA
SCHEMBL13164532 0.83 GPR119 (0.61) GPR119PDK2USP30HSD17B10USP2
SCHEMBL2015994 0.82 RARA (0.50) GPR119PDK2ALDH1A1MAPTLMNA
SCHEMBL12632947 0.82 RARG (0.48) GPR119PDK2ALDH1A1MAPTLMNA
SCHEMBL2014551 0.80 AKT1 (0.46) GPR119PDK2ALDH1A1MAPTLMNA
SCHEMBL12804321 0.79 CKS1B (0.51) GPR119PDK2RARARARBCKS1B
SCHEMBL22955075 0.79 ABCB1 (0.51) GPR119PDK2USP30HSD17B10USP2
SCHEMBL8515152 0.78 GPR119 (0.48) GPR119CKS1BSKP1SKP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9062015-B2 Inhibitors of sphingosine kinase MERCK PATENT GMBH (DE) 2015-06-23 US disclosed
US-9062015-B2 Inhibitors of sphingosine kinase MERCK PATENT GMBH (DE) 2015-06-23 US disclosed
US-9062015-B2 Inhibitors of sphingosine kinase MERCK PATENT GMBH (DE) 2015-06-23 US disclosed
EP-2513057-B1 SPHINGOSINE KINASE INHIBITORS MERCK PATENT GMBH (DE) 2013-09-04 EP disclosed
EP-2513057-A1 SPHINGOSINE KINASE INHIBITORS Merck Patent GmbH (DE) 2012-10-24 EP disclosed
US-20120252789-A1 INHIBITORS OF SPHINGOSINE KINASE MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-10-04 US disclosed
US-20120252789-A1 INHIBITORS OF SPHINGOSINE KINASE MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-10-04 US disclosed
US-20120252789-A1 INHIBITORS OF SPHINGOSINE KINASE MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-10-04 US disclosed
WO-2012069852-A1 PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF SPHINGOSINE KINASE ALMAC DISCOVERY LIMITED (GB) 2012-05-31 WO disclosed
WO-2011072791-A1 SPHINGOSINE KINASE INHIBITORS MERCK PATENT GMBH (DE) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120252789-A1 INHIBITORS OF SPHINGOSINE KINASE SPHK1, SPHK2, S1PR3 GPR119 291/4885PDK2 999/4885USP30 4050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.